Xenon Pharmaceuticals Inc (NASDAQ: XENE)’s stock price has increased by 2.30 compared to its previous closing price of 36.57. However, the company has seen a 0.86% increase in its stock price over the last five trading sessions. globenewswire.com reported 2024-06-05 that VANCOUVER, British Columbia, June 05, 2024 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, today announced that the company will present at the Goldman Sachs 45th Annual Global Healthcare Conference taking place June 10-13, 2024 in Miami, FL.
Is It Worth Investing in Xenon Pharmaceuticals Inc (NASDAQ: XENE) Right Now?
The 36-month beta value for XENE is also noteworthy at 1.25. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for XENE is 73.70M, and at present, short sellers hold a 4.15% of that float. The average trading volume of XENE on June 28, 2024 was 365.59K shares.
XENE’s Market Performance
The stock of Xenon Pharmaceuticals Inc (XENE) has seen a 0.86% increase in the past week, with a -3.11% drop in the past month, and a -13.00% fall in the past quarter. The volatility ratio for the week is 3.22%, and the volatility levels for the past 30 days are at 3.37% for XENE. The simple moving average for the last 20 days is -0.75% for XENE stock, with a simple moving average of -6.64% for the last 200 days.
Analysts’ Opinion of XENE
Many brokerage firms have already submitted their reports for XENE stocks, with Citigroup repeating the rating for XENE by listing it as a “Buy.” The predicted price for XENE in the upcoming period, according to Citigroup is $62 based on the research report published on January 04, 2024 of the current year 2024.
Robert W. Baird, on the other hand, stated in their research note that they expect to see XENE reach a price target of $63. The rating they have provided for XENE stocks is “Outperform” according to the report published on December 08th, 2023.
XENE Trading at -5.48% from the 50-Day Moving Average
After a stumble in the market that brought XENE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -26.63% of loss for the given period.
Volatility was left at 3.37%, however, over the last 30 days, the volatility rate increased by 3.22%, as shares sank -2.30% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -9.83% lower at present.
During the last 5 trading sessions, XENE rose by +0.86%, which changed the moving average for the period of 200-days by +0.08% in comparison to the 20-day moving average, which settled at $37.65. In addition, Xenon Pharmaceuticals Inc saw -18.78% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at XENE starting from GAROFALO ELIZABETH A., who sale 2,092 shares at the price of $45.69 back on Mar 08 ’24. After this action, GAROFALO ELIZABETH A. now owns 0 shares of Xenon Pharmaceuticals Inc, valued at $95,583 using the latest closing price.
GANNON STEVEN, the Director of Xenon Pharmaceuticals Inc, sale 13,000 shares at $46.28 during a trade that took place back on Mar 07 ’24, which means that GANNON STEVEN is holding 2,000 shares at $601,615 based on the most recent closing price.
Stock Fundamentals for XENE
Current profitability levels for the company are sitting at:
- -41.64 for the present operating margin
- 0.3 for the gross margin
The net margin for Xenon Pharmaceuticals Inc stands at -35.06. The total capital return value is set at -0.25. Equity return is now at value -23.95, with -23.02 for asset returns.
Based on Xenon Pharmaceuticals Inc (XENE), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -14.61. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -29.43.
Currently, EBITDA for the company is -210.51 million with net debt to EBITDA at 0.22. When we switch over and look at the enterprise to sales, we see a ratio of 515.77. The receivables turnover for the company is 6.46for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 31.82.
Conclusion
In summary, Xenon Pharmaceuticals Inc (XENE) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
